期刊
JOURNAL OF INFLAMMATION RESEARCH
卷 15, 期 -, 页码 6533-6552出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JIR.S363722
关键词
systemic lupus erythematosus; glomerulonephritis; proteinuria; autoimmunity; steroids
类别
资金
- Deutsche Forschungsgemeinschaft
- Volkswagen Foundation
- [AN372/30-1]
- [97-744]
Lupus nephritis is a severe manifestation of systemic lupus erythematosus, and its treatment still faces many challenges. The progression of chronic kidney disease poses risks to patients, while the development of biomarkers provides hope for personalized treatment.
Lupus nephritis is a severe organ manifestation of systemic lupus erythematosus, and its pathogenesis involves complex etiology and mechanisms. Despite significant knowledge gains and extensive efforts put into understanding the development and relapsing disease activity, lupus nephritis remains a substantial cause of morbidity and mortality in lupus patients. Current therapies retain a significant unmet medical need regarding rates of complete response, preventing relapse of lupus nephritis, progression of chronic kidney disease to kidney failure, drug toxicity, and pill burden-related drug non-adherence. Connected to progression of chronic kidney disease are the associated risks for disabling or even lethal cardiovascular events, as well as chronic kidney disease -related secondary immunodeficiency and serious infections. In this regard, biomarkers are needed that can predict treatment response to specific drugs to enable personalized precision medicine. A series of clinical trials with innovative immunomodulatory drugs are ongoing and raise expectations for improvements in the management of lupus nephritis. Here, we review how new developments in pathogenesis connect with current and future perspectives for the management of lupus nephritis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据